Evidence map›Paper›PMID 41229637›Full record

ArticleEuropean journal of case reports in internal medicine2025

Uncontrolled Graves' Disease as A Driver of Amplified Warfarin Sensitivity.

Esraa Abdulla Ibrahim Ockba, Manar Elfatih Mohamed, Khadija Hafidh

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Esraa Abdulla Ibrahim OckbaInternal Medicine, Dubai Health, Dubai, United Arab Emirates.
Manar Elfatih MohamedInternal Medicine, Dubai Health, Dubai, United Arab Emirates.
Khadija HafidhInternal Medicine, Dubai Health, Dubai, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thyroid function abnormalities can alter the pharmacokinetics of various drugs, including warfarin. Although a few case reports in the literature have highlighted this phenomenon, ours is the first in the region. Case description: We report a case of a 40-year-old female known to have uncontrolled Graves' disease due to non-compliance with medication and follow-up, with a history of mitral valve replacement, on warfarin 3 mg daily. She presented with a headache and was found to have a subdural haematoma and an INR of 10.58. It was observed that as she was approaching euthyroid state with antithyroid treatment; her warfarin requirement slowly increased to maintain the target INR. Conclusion: Our case highlights the relationship between hyperthyroidism and exaggerated response to vitamin K antagonists. Literature suggests there is an amplified response to warfarin in a hyperthyroid state. Therefore, a timely and close follow-up of INR and thyroid function test is warranted in patients with hyperthyroidism on anti-coagulation with warfarin. LEARNING POINTS: Uncontrolled hyperthyroidism can significantly increase warfarin sensitivity, leading to unpredictable and potentially dangerous INR elevations even on low doses.Improvement in thyroid function decreases warfarin sensitivity, often necessitating careful dose adjustment and frequent INR measurement to maintain therapeutic anticoagulation and prevent thrombotic and bleeding complications.Effective management of anti-coagulation in patients with thyroid dysfunction and mechanical heart valves requires multidisciplinary collaboration and patient adherence to optimise outcomes.

Indexed as

anticoagulationhyperthyroidismINRWarfarin

Identifiers

PMID41229637
PMCPMC12604878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.